The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors
Open accessAbstract
Cannabidiol (CBD), the main non-psychotomimetic component of marihuana, exhibits anxiolytic-like properties in many behavioural tests, although its potential for treating major depression has been poorly explored. Moreover, the mechanism of action of CBD remains unclear. Herein, we have evaluated the effects of CBD following acute and chronic administration in the olfactory bulbectomy mouse model of depression (OBX), and investigated the underlying mechanism. For this purpose, we conducted behavioural (open field and sucrose preference tests) and neurochemical (microdialysis and autoradiography of 5-HT1A receptor functionality) studies following treatment with CBD. We also assayed the pharmacological antagonism of the effects of CBD to dissect out the mechanism of action. Our results demonstrate that CBD exerts fast and maintained antidepressant-like effects as evidenced by the reversal of the OBX-induced hyperactivity and anhedonia. In vivo microdialysis revealed that the administration of CBD significantly enhanced serotonin and glutamate levels in vmPFCx in a different manner depending on the emotional state and the duration of the treatment. The potentiating effect upon neurotransmitters levels occurring immediately after the first injection of CBD might underlie the fast antidepressant-like actions in OBX mice. Both antidepressant-like effect and enhanced cortical 5-HT/glutamate neurotransmission induced by CBD were prevented by 5-HT1A receptor blockade. Moreover, adaptive changes in pre- and post-synaptic 5-HT1A receptor functionality were also found after chronic CBD. In conclusion, our findings indicate that CBD could represent a novel fast antidepressant drug, via enhancing both serotonergic and glutamate cortical signalling through a 5-HT1A receptor-dependent mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“, 2009), but also triggers an immediate antidepressant-like effect, similarly to that reported for ketamine (Li et al., 2010; Maeng et al., 2008).”
ResultBisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,311
Anxiety and affective style: role of prefrontal cortex and amygdala
Davidson, R. J. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01328-2 · Cited by 1,135
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059 · cited 2×
“CBD has been reported to act as an antagonist/inverse agonist of CB1 receptors (Thomas et al., 2007) and also to increase anandamide (AEA) levels (Bisogno et al., 2001; Leweke et al., 2012).”
BackgroundA meta‐analytic study of changes in brain activation in depression
Fitzgerald, P. B., Laird, A. R., Maller, J., & Daskalakis, Z. J. (2008) · Human Brain Mapping · doi:10.1002/hbm.20426 · Cited by 903
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · cited 2×
“, 2002), has shown anxiolytic properties both in humans and rodents (Bergamaschi et al., 2011; Guimaraes et al., 1990) after acute”
BackgroundThomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 756
The olfactory bulbectomised rat as a model of depression
Song, C., & Leonard, B. E. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.010 · Cited by 698
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160105897 · Cited by 669
Endocannabinoids Mediate Neuron-Astrocyte Communication
Navarrete, M., & Araque, A. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.029 · Cited by 581
5-HT1A receptor function in major depressive disorder
Savitz, J., Lucki, I., & Drevets, W. C. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.01.009 · Cited by 574
McPartland, J. M., Duncan, M., Di Marzo, V., & Pertwee, R. G. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12944 · Cited by 521
Neurogenesis and generalization: a new approach to stratify and treat anxiety disorders
Kheirbek, M. A., Klemenhagen, K. C., Sahay, A., & Hen, R. (2012) · Nature Neuroscience · doi:10.1038/nn.3262 · Cited by 508
Cannabidiol: An Overview of Some Pharmacological Aspects
Mechoulam, R., Parker, L. A., & Gallily, R. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb05998.x · Cited by 508
Celada, P., Puig, M. V., Casanovas, J. M., Guillazo, G., & Artigas, F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09917.2001 · Cited by 497 · cited 5×
“neurons, driving to a 5-HT increase in mPFCx (Celada et al., 2001).”
BackgroundInfluentialAppetite suppression and weight loss after the cannabinoid antagonist SR 141716
Colombo, G., Agabio, R., Diaz, G., Lobina, C., Reali, R., & Gessa, G. L. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00322-1 · Cited by 487
Santana, N. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh070 · Cited by 486
Sim, L. J., Selley, D. E., & Childers, S. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7242 · Cited by 455
Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., Cipriano, M., Carratù, M. R., Iuvone, T., & Steardo, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028668 · Cited by 410 · cited 2×
“It also restores the impaired neuroproliferation of chronically stressed animals (Campos et al., 2013b), and presents anti-inflammatory and immunomodulatory effects (Esposito et al., 2011; Malfait et al., 2000).”
BackgroundEmerging role of glutamate in the pathophysiology of major depressive disorder
Hashimoto, K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.005 · Cited by 381
Antianxiety effect of cannabidiol in the elevated plus-maze
Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., & Zuardi, A. W. (1990) · Psychopharmacology · doi:10.1007/bf02244012 · Cited by 379 · cited 2×
“…the main nonpsychotomimetic component of marijuana (Mechoulam et al., 2002), has shown anxiolytic properties both in humans and rodents (Bergamaschi et al., 2011; Guimaraes et al., 1990) after acute or chronic administration (Campos and Guimaraes, 2008; Campos et al., 2013b; Resstel et al., 2009).”
BackgroundAntidepressant‐like effects of cannabidiol in mice: possible involvement of 5‐HT1Areceptors
Zanelati, T., Biojone, C., Moreira, F., Guimarães, F., & Joca, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00521.x · Cited by 366
Campos, A. C., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1168-x · Cited by 364
Fernández‐Ruiz, J., Sagredo, O., Pazos, M. R., García, C., Pertwee, R., Mechoulam, R., & Martínez‐Orgado, J. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04341.x · Cited by 349
Bambico, F. R., Katz, N., Debonnel, G., & Gobbi, G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-07.2007 · Cited by 325 · cited 2×
“For this reason, the study of the endocannabinoid system and cannabinoid derivatives has gained a great interest in anxiety/depression research (Bambico et al., 2007; Hill and Gorzalka, 2005; McLaughlin et al., 2007; Shearman et al., 2003).”
BackgroundCampos, A. C., Ortega, Z., Palazuelos, J., Fogaça, M. V., Aguiar, D. C., Díaz-Alonso, J., Ortega-Gutiérrez, S., Vázquez-Villa, H., Moreira, F. A., Guzmán, M., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001502 · Cited by 313 · cited 12×
“It was proposed as a putative novel antidepressant as it displayed positive responses in the forced swimming test (FST) (El-Alfy et al., 2010; Zanelati et al., 2010) and also in the novelty suppressed feeding test (NSF) under chronic stress conditions (Campos et al., 2013b).”
BackgroundResultInfluentialCosta, B., Giagnoni, G., Franke, C., Trovato, A. E., & Colleoni, M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705920 · Cited by 289
Resstel, L. B. M., Tavares, R. F., Lisboa, S. F. S., Joca, S. R. L., Corrêa, F. M. A., & Guimarães, F. S. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00046.x · Cited by 283
El-Alfy, A. T., Ivey, K., Robinson, K., Ahmed, S., Radwan, M., Slade, D., Khan, I., ElSohly, M., & Ross, S. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.03.004 · Cited by 268
Rock, E., Bolognini, D., Limebeer, C., Cascio, M., Anavi‐Goffer, S., Fletcher, P., Mechoulam, R., Pertwee, R., & Parker, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01621.x · Cited by 255
Pazos, M. R., Mohammed, N., Lafuente, H., Santos, M., Martínez-Pinilla, E., Moreno, E., Valdizan, E., Romero, J., Pazos, A., Franco, R., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.027 · Cited by 225
Self-citationAnxiolytic-like effect of cannabidiol in the rat Vogel conflict test
Moreira, F. A., Aguiar, D. C., & Guimarães, F. S. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.004 · Cited by 207
Raphe GABAergic Neurons Mediate the Acquisition of Avoidance after Social Defeat
Challis, C., Boulden, J., Veerakumar, A., Espallergues, J., Vassoler, F. M., Pierce, R. C., Beck, S. G., & Berton, O. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2383-13.2013 · Cited by 197 · cited 1×
“Indeed, a sensitization of GABAergic interneurons was reported in DRN in the social defeat animal model of depression (Challis et al., 2013).”
BackgroundGardier, A., Malagié, I., Trillat, A., Jacquot, C., & Artigas, F. (1996) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.1996.tb00145.x · Cited by 197
Hill, M. N., & Gorzalka, B. B. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00006 · Cited by 192
Shearman, L. P., Rosko, K. M., Fleischer, R., Wang, J., Xu, S., Tong, X. S., & Rocha, B. A. (2003) · Behavioural Pharmacology · doi:10.1097/00008877-200312000-00001 · Cited by 186
López-Gil, X., Babot, Z., Amargós-Bosch, M., Suñol, C., Artigas, F., & Adell, A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301356 · Cited by 183
Self-citationLlado-Pelfort, L., Santana, N., Ghisi, V., Artigas, F., & Celada, P. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr220 · Cited by 156
Fogaça, M. V., Reis, F. M. C. V., Campos, A. C., & Guimarães, F. S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.012 · Cited by 153 · cited 4×
“CBD did not alter locomotor activity or central ambulation in sham animals.”
BackgroundResultInfluentialMagen, I., Avraham, Y., Ackerman, Z., Vorobiev, L., Mechoulam, R., & Berry, E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00589.x · Cited by 143
Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors
Casarotto, P. C., Gomes, F. V., Resstel, L. B. M., & Guimarães, F. S. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833b33c5 · Cited by 141 · cited 4×
“This multifaceted drug produces different pharmacological actions modulating several receptors in the central nervous system (CNS) (CB1, CB2, 5-HT1A, TRPV1 and PPARg receptors, among others) (Campos et al., 2013a, 2013b; Casarotto et al., 2010; Costa et al., 2004; Do Monte et al., 2013; Esposito et al., 2011; Pazos et…”
BackgroundInfluentialAdams, B. W., & Moghaddam, B. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01195-7 · Cited by 134
Cannabidiol decreases body weight gain in rats: Involvement of CB2 receptors
Ignatowska-Jankowska, B. M., Jankowski, M. M., & Swiergiel, A. H. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.12.031 · Cited by 133
Ohl, F. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00084-7 · Cited by 127
McLaughlin, R. J., Hill, M. N., Bambico, F. R., Stuhr, K. L., Gobbi, G., Hillard, C. J., & Gorzalka, B. B. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.01.004 · Cited by 122
Beyer, C. E., Boikess, S., Luo, B., & Dawson, L. A. (2002) · Journal of Psychopharmacology · doi:10.1177/026988110201600403 · Cited by 114
Soares, V. D. P., Campos, A. C., Bortoli, V. C. D., Zangrossi, H., Guimarães, F. S., & Zuardi, A. W. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.004 · Cited by 112 · cited 8×
“…properties of CBD are predominantly mediated by 5-HT1A receptors (Campos et al., 2013a; Campos and Guimaraes, 2008; Resstel et al., 2009; Soares Vde et al., 2010; Zanelati et al., 2010), whereas the anxiolytic-like effects induced by its chronic administration involving neurogenic actions,…”
BackgroundResultInfluentialAnxiogenic-like effects of chronic cannabidiol administration in rats
ElBatsh, M. M., Assareh, N., Marsden, C. A., & Kendall, D. A. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2566-z · Cited by 100
Cannabinol and cannabidiol exert opposing effects on rat feeding patterns
Farrimond, J. A., Whalley, B. J., & Williams, C. M. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2697-x · Cited by 97
Infusion of cannabidiol into infralimbic cortex facilitates fear extinction via CB1 receptors
Monte, F. H. D., de Souza, R. R., de Bitencourt, R. M., Kroon, J. A. V., & Takahashi, R. N. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.04.045 · Cited by 97
McCarberg, B. H., & Barkin, R. L. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3180a5e581 · Cited by 86
McLaughlin, R. J., Hill, M. N., Morrish, A. C., & Gorzalka, B. B. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282ee7b44 · Cited by 86
Rodríguez‐Gaztelumendi, A., Rojo, M. L., Pazos, Á., & Díaz, Á. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05898.x · Cited by 80
Self-citationCannabidiol inhibits the hyperphagia induced by cannabinoid-1 or serotonin-1A receptor agonists
Scopinho, A. A., Guimarães, F. S., Corrêa, F. M. D. A., & Resstel, L. B. M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.01.007 · Cited by 71
Campos, A. C., de Paula Soares, V., Carvalho, M. C., Ferreira, F. R., Vicente, M. A., Brandão, M. L., Zuardi, A. W., Zangrossi, H., & Guimarães, F. S. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2878-7 · Cited by 65
Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action
Du, J., Machado-Vieira, R., Maeng, S., Martinowich, K., Manji, H. K., & Zarate, C. A. (2006) · Drug Discovery Today: Therapeutic Strategies · doi:10.1016/j.ddstr.2006.11.012 · Cited by 64
Mendiguren, A., & Pineda, J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00434.x · Cited by 50
Saitoh, A., Yamaguchi, K., Tatsumi, Y., Murasawa, H., Nakatani, A., Hirose, N., Yamada, M., Yamada, M., & Kamei, J. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0699-x · Cited by 39
Social isolation differentially affects anxiety and depressive-like responses of bulbectomized mice
Linge, R., Pazos, Á., & Díaz, Á. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.01.041 · Cited by 28
Self-citationRossi, D. V., Valdez, M., Gould, G. G., & Hensler, J. G. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005754 · Cited by 28
Neuropharmacologic Studies on the Brain Serotonin1A Receptor Using the Selective Agonist Osemozotan
Matsuda, T. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00645 · Cited by 27
Olfactory bulbectomy alters NMDA receptor levels in the rat prefrontal cortex
Webster, H. H., Flores, G., Marcotte, E. R., Cécyre, D., Quirion, R., & Srivastava, L. K. (2000) · Synapse · doi:10.1002/1098-2396(200008)37:2<159::aid-syn9>3.0.co;2-n · Cited by 26
The 5-HT1A Receptor: A Signaling Hub Linked to Emotional Balance
Chattopadhyay, A. (2007) · CRC Press eBooks · doi:10.1201/9781420005752-12 · Cited by 15
Cited by
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
Cannabidiol Adverse Effects and Toxicity
Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190603171901 · Cited by 468
Cannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306
Metadata
- Authors
- Linge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, A., Adell, A., & Díaz, Á.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 103
- Pages
- 16-26
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2220591944
- Cited by
- 279
- References
- 64
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.